NASDAQ:QDEL QuidelOrtho (QDEL) Stock Price, News & Analysis $39.67 +0.70 (+1.80%) Closing price 03/5/2025 04:00 PM EasternExtended Trading$39.60 -0.08 (-0.19%) As of 03/5/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About QuidelOrtho Stock (NASDAQ:QDEL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get QuidelOrtho alerts:Sign Up Key Stats Today's Range$38.77▼$40.1550-Day Range$38.97▼$47.6152-Week Range$29.74▼$49.45Volume627,594 shsAverage Volume939,549 shsMarket Capitalization$2.67 billionP/E RatioN/ADividend YieldN/APrice Target$51.20Consensus RatingModerate Buy Company OverviewQuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.Read More… QuidelOrtho Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks90th Percentile Overall ScoreQDEL MarketRank™: QuidelOrtho scored higher than 90% of companies evaluated by MarketBeat, and ranked 96th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingQuidelOrtho has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageQuidelOrtho has only been the subject of 4 research reports in the past 90 days.Read more about QuidelOrtho's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth39.57% Earnings GrowthEarnings for QuidelOrtho are expected to grow by 39.57% in the coming year, from $2.30 to $3.21 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of QuidelOrtho is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of QuidelOrtho is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQuidelOrtho has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about QuidelOrtho's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.53% of the float of QuidelOrtho has been sold short.Short Interest Ratio / Days to CoverQuidelOrtho has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in QuidelOrtho has recently increased by 27.57%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldQuidelOrtho does not currently pay a dividend.Dividend GrowthQuidelOrtho does not have a long track record of dividend growth. Sustainability and ESG3.8 / 5Environmental Score-2.61 Percentage of Shares Shorted6.53% of the float of QuidelOrtho has been sold short.Short Interest Ratio / Days to CoverQuidelOrtho has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in QuidelOrtho has recently increased by 27.57%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment1.42 News SentimentQuidelOrtho has a news sentiment score of 1.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for QuidelOrtho this week, compared to 8 articles on an average week.MarketBeat FollowsOnly 1 people have added QuidelOrtho to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, QuidelOrtho insiders have bought more of their company's stock than they have sold. Specifically, they have bought $249,887.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.00% of the stock of QuidelOrtho is held by insiders.Percentage Held by Institutions99.00% of the stock of QuidelOrtho is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about QuidelOrtho's insider trading history. Receive QDEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for QuidelOrtho and its competitors with MarketBeat's FREE daily newsletter. Email Address QDEL Stock News HeadlinesIs QuidelOrtho Corporation (QDEL) the Best Medical Technology Stock to Buy According to Analysts?March 5 at 1:08 AM | insidermonkey.comQuidelOrtho to Participate in the 46th Annual Raymond James Institutional Investor ConferenceFebruary 24, 2025 | finance.yahoo.comHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance to walk away with gains as high as 235%, 459%, and 700% - all while the stock market got cut in half. Could he be right again?March 6, 2025 | Behind the Markets (Ad)QuidelOrtho: Growth Struggles And Negative GAAP Earnings Continue To Disinterest InvestorsFebruary 20, 2025 | seekingalpha.comQuidelOrtho's SWOT analysis: stock poised for growth amid challengesFebruary 17, 2025 | msn.comQuidelOrtho Full Year 2024 Earnings: EPS Misses ExpectationsFebruary 15, 2025 | finance.yahoo.comT. Rowe Price Investment Management, Inc. Increases Stake in QuidelOrtho CorpFebruary 14, 2025 | gurufocus.comQuidelOrtho’s Earnings Call: Mixed Sentiment Amidst Revenue DeclineFebruary 13, 2025 | tipranks.comSee More Headlines QDEL Stock Analysis - Frequently Asked Questions How have QDEL shares performed this year? QuidelOrtho's stock was trading at $44.55 at the beginning of 2025. Since then, QDEL shares have decreased by 11.0% and is now trading at $39.67. View the best growth stocks for 2025 here. How were QuidelOrtho's earnings last quarter? QuidelOrtho Co. (NASDAQ:QDEL) announced its quarterly earnings data on Wednesday, February, 12th. The company reported $0.63 earnings per share for the quarter, missing analysts' consensus estimates of $1.07 by $0.44. QuidelOrtho had a positive trailing twelve-month return on equity of 3.78% and a negative net margin of 72.84%. Who are QuidelOrtho's major shareholders? QuidelOrtho's top institutional investors include T. Rowe Price Investment Management Inc. (16.71%), Vanguard Group Inc. (10.14%), Invesco Ltd. (5.13%) and ArrowMark Colorado Holdings LLC (2.94%). Insiders that own company stock include Brian J Blaser, Joseph M Busky, Carlyle Group Inc and Mary Lake Ph D Polan. View institutional ownership trends. How do I buy shares of QuidelOrtho? Shares of QDEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of QuidelOrtho own? Based on aggregate information from My MarketBeat watchlists, some other companies that QuidelOrtho investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), PayPal (PYPL), Salesforce (CRM) and CrowdStrike (CRWD). Company Calendar Last Earnings2/12/2025Today3/05/2025Next Earnings (Estimated)5/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryHealth Care Supplies Current SymbolNASDAQ:QDEL CIK353569 Webwww.quidel.com Phone(800) 874-1517Fax858-453-4338Employees7,100Year Founded1979Price Target and Rating Average Stock Price Target$51.20 High Stock Price Target$61.00 Low Stock Price Target$43.00 Potential Upside/Downside+29.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($30.28) Trailing P/E RatioN/A Forward P/E Ratio17.25 P/E GrowthN/ANet Income$-2,027,000,000.00 Net Margins-72.84% Pretax Margin-76.59% Return on Equity3.78% Return on Assets1.80% Debt Debt-to-Equity Ratio0.71 Current Ratio1.22 Quick Ratio0.69 Sales & Book Value Annual Sales$2.78 billion Price / Sales0.96 Cash Flow$30.75 per share Price / Cash Flow1.29 Book Value$44.75 per share Price / Book0.89Miscellaneous Outstanding Shares67,257,000Free Float66,584,000Market Cap$2.67 billion OptionableOptionable Beta0.08 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:QDEL) was last updated on 3/6/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | Sponsored77 Hedge Funds Are Betting On This Off-Radar MineralWith surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fa...The Tomorrow Investor | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredTrillion-Dollar Crypto PlayAI is Creating Fortunes… (but not where you think!) Bryce Paul and the team at Crypto101 just released a br...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding QuidelOrtho Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share QuidelOrtho With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.